Skip to Main Content

INFORMATION FOR

Study to Assess the Efficacy and Safety of Setrusumab in Participants With Osteogenesis Imperfecta

Conditions

Diseases of the Musculoskeletal System

Phase II-III

What is the purpose of this trial?

The primary objectives of the study are to identify a dose(s) of setrusumab based on safety and pharmacodynamic (PD) effects in participants with OI and to evaluate the effect of setrusumab vs placebo on reduction in total fracture rate.

  • Trial with
    Ultragenyx Pharmaceutical, Inc.
  • Start Date
    04/28/2022
  • End Date
    03/31/2025

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/15/2022
  • Study HIC
    #2000031756